Pill combo could replace chemo for tough leukemia

NCT ID NCT04817241

First seen Nov 10, 2025 · Last updated May 14, 2026 · Updated 23 times

Summary

This study tests whether an all-oral combination of ASTX727 (a pill form of decitabine) plus venetoclax works as well as standard chemotherapy for younger adults (18-65) with high-risk acute myeloid leukemia (AML) that lacks a FLT3 mutation. The trial has two phases: first, finding a safe dose, then comparing the oral combo to standard chemo for event-free survival. Only 5 participants were enrolled, so results are very early.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Montefiore Medical Center - Moses Campus

    The Bronx, New York, 10467, United States

  • Montefiore Medical Center-Einstein Campus

    The Bronx, New York, 10461, United States

  • Roswell Park Cancer Institute

    Buffalo, New York, 14263, United States

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama, 35233, United States

  • University of Virginia Cancer Center

    Charlottesville, Virginia, 22908, United States

  • Vanderbilt University/Ingram Cancer Center

    Nashville, Tennessee, 37232, United States

  • Yale University

    New Haven, Connecticut, 06520, United States

Conditions

Explore the condition pages connected to this study.